The potential role of non-FDG-PET in the management of head and neck cancer

Oral Oncology

Volumn 47, Issue 1, 2011, Pages 2-7

  Heuveling, Derrek A ^a   De Bree, Remco ^a   Van Dongen, Guus A M S ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Head and neck cancer; Hypoxia; Metabolic imaging; Molecular imaging; Oral cancer; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR;

CANCER RADIOTHERAPY; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; GLUCOSE METABOLISM; HEAD AND NECK CANCER; HUMAN; HYPOXIA; MOLECULARLY TARGETED THERAPY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79551572429     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2010.10.008     Document Type: Review

References (71)

1. R. De Bree, J.A. Castelijns, O.S. Hoekstra, and C.R. Leemans Advances in imaging in the work-up of head and neck cancer patients Oral Oncol 45 2009 930 935
2. I. Verel, G.W.M. Visser, and G.A.M.S. van Dongen The promise of immuno-PET in radioimmunotherapy J Nucl Med 46 2005 164S 171S
3. K.E. Rusthoven, M. Koshy, and A.C. Paulino The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor Cancer 101 2004 2641 2649
4. J. Johansen, S. Buus, A. Loft, S. Keiding, M. Overgaard, and H.S. Hansen Prospective study of FDG-PET in the detection and management of patients with lymph node metastases to the neck from an unknown primary tumor Results from the Dahanca-13 study Head Neck 30 2008 471 478
5. 18F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors Oral Oncol 45 2009 218 224
6. 18F-FDG PET and extended-field multi-detector row CT Neuroradiology 50 2008 969 979
7. A. Senft, R. de Bree, O.S. Hoekstra, D.J. Kuik, R.P. Golding, and W.J.G. Oyen Screening for distant metastases in head and neck cancer patients by chest CT or whole body FDG-PET: A prospective multicenter trial Radiother Oncol 87 2008 221 229
8. C.A. Krabbe, J. Pruim, B.F.A.M. van der Laan, L.A. Rodiger, and J.L.N. Roodenburg FDG-PET and detection of distant metastases and simultaneous tumors in head and neck squamous cell carcinoma: A comparison with chest radiography and chest CT Oral Oncol 45 2009 234 240
9. R. De Bree, L. Van der Putten, J. Brouwer, J.A. Castelijns, O.S. Hoekstra, and C.R. Leemans Detection of locoregional recurrent head and neck cancer after (chemo)radiotherapy using modern imaging Oral Oncol 45 2009 386 393
10. M.G. Isles, C. McConkey, and H.M. Mehanna A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy Clin Otolaryngol 33 2008 210 222
11. 18F]-fluorodeoxyglucose positron emission tomography imaging in management of head-and-neck cancer-a long-term outcome report Int J Radiat Oncol Biol Phys 74 2009 9 14
12. 18F] fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer J Clin Oncol 27 2009 2509 2525
13. S.C. Burrell, and A.D. Van den Abbeele 2-Deoxy-2-[F-18]fluoro-d-glucose- positron emission tomography of the head and neck: an atlas of normal uptake and variants Mol Imaging Biol 7 2005 244 256
14. S.M. Larson, and H. Schoder New PET tracers for evaluation of solid tumor response to therapy Q J Nucl Med Mol Imaging 53 2009 158 166
15. 18 fluoro-l-thymidine: a comprehensive evaluation Nucl Med Comm 30 2009 908 917
16. 18F-FDG PET J Nucl Med 45 2004 226 231
17. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients J Nucl Med 48 2007 726 735
18. 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors J Nucl Med 51 2010 866 874
19. 18F-FLT) in head and neck cancer patients before and early after initiation of chemoradiation therapy J Nucl Med 50 2009 1028 1035
20. 18F-3-deoxy-3-fluorothymidine measurements using positron emission tomography Eur J Nucl Med Mol Imaging 36 2009 389 395
21. 18F]FDG-PET in the evaluation of radiotherapy for laryngeal cancer Oral Oncol 45 2009 e211 e215
22. 18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice J Nucl Med 45 2004 1754 1758
23. 18F]fluoro-3-deoxythymidine (FLT) Mol Imaging Biol 9 2007 340 347
24. 18F-FDG PET and CT in patients with head and neck cancer J Nucl Med 47 2006 256 261
25. S. Balogova, S. Perie, K. Kerrou, D. Grahek, F. Montravers, and B. Angelard Prospective comparison of FDG and FET PET/CT in patients with head and neck squamous cell carcinoma Mol Imaging Biol 10 2008 364 373
26. 18F]-fluoro-alpha- methyltyrosine (FMT) PET: a comparative study with FDG-PET Ann Nucl Med 21 2007 129 135
27. S. Leskinen-Kallio, K. Nagren, P. Lehikoinen, U. Ruotsalainen, M. Teras, and H. Joensuu Carbon-11-Methionine and PET is an effective method to image head and neck cancer J Nucl Med 33 1992 691 695
28. P. Lindholm, S. Leskinen, and M. Lapela Carbon-11-Methionine uptake in squamous cell head and neck cancer J Nucl Med 39 1998 1393 1397
29. 11C-methionine positron emission tomography Oral Oncol 45 2009 703 705
30. 18F-fluorodeoxyglucose and carbon-11-methionine in head and neck cancer J Nucl Med 34 1993 1711 1716
31. 11C-methionine positron emission tomography for the delineation of the tumor volume in pharyngo-laryngeal squamous cell carcinoma: Comparison with FDG-PET and CT Radiother Oncol 71 2004 267 273
32. 11C]methionine-positron emission tomography Radiother Oncol 52 1999 225 232
33. 11C-methionine PET, correlation with morphologic response, and clinical outcome J Nucl Med 44 2003 526 532
34. D.M. Brizel, G.S. Sibley, L.R. Prosnitz, R.L. Scher, and M.W. Dewhirst Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck Int J Radiat Oncol Biol Phys 38 1997 285 289
35. M. Nordsmark, S.M. Bentzen, V. Rudat, D. Brizel, E. Lartigau, and P. Stadler Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy An international multi-center study. Radiother Oncol 77 2005 18 24
36. C.C. Ling, J. Humm, S. Larson, H. Amols, Z. Fuks, and S. Leibel Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality Int J Radiat Oncol Biol Phys 47 2000 551 560
37. A.L. Grosu, M. Souvatzoglou, B. Roper, M. Dobritz, N. Wiedenmann, and V. Jacob Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer Int J Radiat Oncol Biol Phys 69 2007 541 551
38. P. Lambin, S.F. Petit, H.J.W.L. Aerts, W.J.C. Van Elmpt, C.J.G. Oberije, and M.H.W. Starmans The ESTRO Breur Lecture 2009. From population to voxel-based radiotherapy: exploiting intra-tumour and intra-organ heterogeneity for advanced treatment of non-small cell lung cancer Radiother Oncol 96 2 2010 145 152
39. J.H.A.M. Kaanders, L.A.M. Pop, H.A.M. Marres, I. Bruaset, F.J.A. Van den Hoogen, and M.A.W. Merkx ARCON: experience in 215 patients with advanced head-and-neck cancer Int J Radiat Oncol Biol Phys 52 2002 769 778
40. D. Rischin, L.J. Peters, B. OSullivan, J. Giralt, R. Fisher, and K. Yuen Tirapazamine, cisplatin, and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group J Clin Oncol 28 2010 2989 2995
41. J. Russell, S. Carlin, S.A. Burke, B. Wen, K.M. Yang, and C.C. Ling Immunohistochemical detection of changes in tumor hypoxia Int J Radiat Oncol Biol Phys 73 2009 1177 1186
42. 18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02 J Clin Oncol 24 2006 2098 2104
43. J.G. Rajendran, D.L. Schwartz, J. OSullivan, L.M. Peterson, P. Ng, and J. Scharnhorst Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer Clin Cancer Res 12 2006 5435 5441
44. R.J. Hicks, D. Rischin, R. Fisher, D. Binns, A.M. Scott, and L.J. Peters Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent Eur J Nucl Med Mol Imaging 32 2005 1384 1391
45. 18F]FMISO in an experimental mammary carcinoma Eur J Nucl Med Mol Imaging 31 2004 513 520
46. 18F]FETNIM: a potential marker for PET J Nucl Med 42 2001 1397 1404
47. 18F]EF3 in patients with head and neck tumours: a phase I study to assess the tracer pharmacokinetics, biodistribution and metabolism Eur J Nucl Med Mol Imaging 35 2008 1282 1289
48. 18F-EF5: A new PET tracer for imaging hypoxia in head and neck cancer J Nucl Med 49 2008 1944 1951
49. 18F-fluoroazomycin arabinoside J Nucl Med 46 2005 106 113
50. 18F]FAZA-first small animal PET results J Pharm Pharm Sci 10 2007 203 211
51. 18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors Nucl Med Biol 30 2003 317 326
52. 18F-FAZA) Eur J Nucl Med Mol Imaging 36 2009 1565 1573
53. 18F]FAZA PET in head and neck cancer patients: a pilot study Eur J Nucl Med Mol Imaging 34 2007 1566 1575
54. J.P. Holland, J.S. Lewis, and F. Dehdashti Assessing tumor hypoxia by positron emission tomography with Cu-ATSM Q J Nucl Med Mol Imaging 53 2009 193 200
55. R.I. Haddad, and D.M. Shin Recent advances in head and neck cancer N Engl J Med 359 2008 1143 1154
56. J.A. Bonner, P.M. Harari, J. Giralt, N. Azarnia, D.M. Shin, and R.B. Cohen Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 2006 567 578
57. T.Y. Seiwert, and E.E.W. Cohen Targeting angiogenesis in head and neck cancer Semin Oncol 35 2008 274 285
58. J. Bernier, S.M. Bentzen, and J.B. Vermorken Molecular therapy in head and neck oncology Nat Rev Clin Oncol 6 2009 266 277
59. G.A.M.S. Van Dongen, G.W.M. Visser, M.N. Lub-De Hooge, E.G. De Vries, and L.R. Perk Immuno-PET: A navigator in monoclonal antibody development and applications Oncologist 12 2007 1379 1389
60. G.A.M.S. Van Dongen, and M.W.J.D. Vosjan Immuno-positron emission tomography: shedding light on clinical antibody therapy Cancer Biother Radiopharm 25 4 2010 375 385
61. P.K.E. Borjesson, Y.W.S. Jauw, R. Boellaard, R. de Bree, E.F.I. Comans, and J.C. Roos Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients Clin Cancer Res 12 2006 2133 2140
62. A.H.G.J. Schrijvers, J.J. Quak, A.M. Uyterlinde, M. van Walsum, C.J.L.M. Meijer, and G.B. Snow MAb U36, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck Cancer Res 53 1993 4383 4390
63. 89Zr-labeled cetuximab uptake assessed with PET J Nucl Med 50 2009 123 131
64. 177Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab J Nucl Med 46 2005 1898 1906
65. W.B. Nagengast, E.G. de Vries, G.A. Hospers, N.H. Mulder, J.R. de Jong, and H. Hollema In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft J Nucl Med 48 2007 1313 1319
66. 89Zr-labelled monoclonal antibody DN30 Eur J Nucl Med Mol Imaging 35 2008 1857 1867
67. 89Zr-labeled cG250 monoclonal antibody in nude rats Cancer Biother Radiopharm 19 2004 155 163
68. D. Neri, and R. Bicknell Tumour vascular targeting Nat Rev Cancer 5 2005 436 446
69. 131I-L19-SIP radioimmunotherapy Eur J Nucl Med Mol Imaging 36 2009 1235 1244
70. F.A. Shepherd, J. Rodrigues Pereira, T. Ciuleanu, E.H. Tan, V. Hirsh, and S. Thongprasert Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132
71. 11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts Cancer Res 69 2009 873 878